Rapport closes $215.7 million stock offering and $172.5 million convertible notes sale
Both offerings closed October 30, 2026, with underwriters fully exercising options on shares and notes, as Rapport advances RAP-219 toward Phase 3 trials in epilepsy and bipolar mania.
SEC filing (8)